Perfusion Services, Heart Vascular and Thoracic Institute, Cleveland Clinic, PO BOX 112412, Abu Dhabi, United Arab Emirates.
Critical Care Institute, Cleveland Clinic, PO BOX 112412, Abu Dhabi, United Arab Emirates - Cleveland Clinic Lerner College of Medicine, Western Reserve University, 44195 Ohio, USA.
J Extra Corpor Technol. 2024 Sep;56(3):136-144. doi: 10.1051/ject/2024015. Epub 2024 Sep 20.
Heparin, a commonly used anticoagulant in cardiac surgery, binds to antithrombin III (ATIII) to prevent clot formation. However, heparin resistance (HR) can complicate surgical procedures, leading to increased thromboembolic risks and bleeding complications. Proper diagnosis and management of HR are essential for optimizing surgical outcomes.
Diagnosis of HR involves assessing activated clotting time (ACT) and HR assays. Management strategies were identified through a comprehensive review of the literature, including studies exploring heparin dosage adjustments, antithrombin supplementation, and alternative anticoagulants in cardiac surgery patients with HR. A thorough search of relevant studies on HR was conducted using multiple scholarly databases and relevant keywords, resulting in 59 studies that met the inclusion criteria.
HR occurs when patients do not respond adequately to heparin therapy, requiring higher doses or alternative anticoagulants. Mechanisms of HR include AT III deficiency, PF4 interference, and accelerated heparin clearance. Diagnosis involves assessing ACT and HR assays. HR in cardiac surgery can lead to thromboembolic events, increased bleeding, prolonged hospital stays, and elevated healthcare costs. Management strategies include adjusting heparin dosage, supplementing antithrombin levels, and considering alternative anticoagulants. Multidisciplinary management of HR involves collaboration among various specialities. Strategies include additional heparin doses, fresh frozen plasma (FFP) administration, and antithrombin concentrate supplementation. Emerging alternatives to heparin, such as direct thrombin inhibitors and nafamostat mesilate, are also being explored.
Optimizing the management of HR is crucial for improving surgical outcomes and reducing complications in cardiac surgery patients. Multidisciplinary approaches and emerging anticoagulation strategies hold promise for addressing this challenge effectively.
肝素是心脏手术中常用的抗凝剂,它与抗凝血酶 III(ATIII)结合以防止血栓形成。然而,肝素抵抗(HR)会使手术过程复杂化,导致血栓栓塞风险增加和出血并发症增加。正确诊断和管理 HR 对于优化手术结果至关重要。
HR 的诊断包括评估激活凝血时间(ACT)和 HR 测定。通过全面审查文献,包括研究探索 HR 心脏手术患者中肝素剂量调整、抗凝血酶补充和替代抗凝剂的管理策略,确定了管理策略。使用多个学术数据库和相关关键字对 HR 的相关研究进行了彻底搜索,最终有 59 项符合纳入标准的研究。
当患者对肝素治疗反应不足时,即需要更高剂量或替代抗凝剂时,就会发生 HR。HR 的机制包括 ATIII 缺乏、PF4 干扰和肝素清除加速。诊断包括评估 ACT 和 HR 测定。心脏手术中的 HR 可导致血栓栓塞事件、出血增加、住院时间延长和医疗保健费用增加。管理策略包括调整肝素剂量、补充抗凝血酶水平和考虑替代抗凝剂。HR 的多学科管理涉及多个专业的合作。策略包括额外的肝素剂量、新鲜冷冻血浆(FFP)的给予和抗凝血酶浓缩物的补充。肝素的新兴替代品,如直接凝血酶抑制剂和甲萘醌,也正在探索中。
优化 HR 的管理对于改善心脏手术患者的手术结果和减少并发症至关重要。多学科方法和新兴的抗凝策略有望有效地应对这一挑战。